Healthcare. We Care.

Aspen concludes acquisition API business from from MSD

Published 1 Oct 2013

Oss, The Netherlands – JSE Limited listed Aspen Holdings, the ninth largest generic pharmaceutical company in the world, announced today that the Aspen Group (“Aspen”) has finalized the acquisition of Active Pharmaceutical Ingredients (API) manufacturing operations and related businesses (“the API business”) from MSD, known as Merck & Co., Inc. in the US and Canada.

Stephen Saad, Aspen Group Chief Executive, said “this deal strongly complements Aspen’s strategic intent

of globalising its business by providing access to a niche range of APIs and products. It includes the acquisition of 2 API production facilities in Oss-The Netherlands as well as a satellite facility and a sales office in the United States”.

Throughout the negotiations both companies have been meticulous to not disturb the primary business activities and committed to ensure a smooth and orderly transfer of the business and continuity of the API supply from Oss to 3rd party customers. As from today, we will continue to operate under our new legal entity Aspen Oss B.V.

The change to Aspen Oss B.V. will not have any impact on our manufacturing locations. Aspen Oss B.V. will continue to produce APIs in our facilities ‘Diosite’ and ‘Moleneind’, without any modification of the production processes and cGMP status of either facility. For more information on the acquisition announced today, please contact your regular contact at Aspen Oss B.V. or send a message to

  • All sites
  • Africa Middle East
  • Americas
  • Asia
  • Australasia
  • Europe CIS